Meet our expert Anna Nordmark
“In my job I really appreciate helping life-science companies get the most out of the interactions with regulatory authorities, MPA, EMA or FDA. Here I can use my background to bridge between pharma and regulatory agencies”
Why is a thorough regulatory strategy the foundation of every development program?
Early discussions on development plan and strategy with regulatory authorities in Europe and US are of great importance in any drug development project and help navigate through a sometimes complex regulatory environment. This will identify potential hurdles and possible opportunities such as conditional approval and orphan designation. It is equally important to balance between science and regulatory requirement.
Dr Anna Nordmark brings 10 years of experience from AstraZeneca within preclinical and clinical development and six years from the Medical Products Agency.
A comprehensive regulatory and scientifically sound strategy from the beginning may be the difference between success and failure. How can we help you?